Hsbc Holdings PLC Decreases Holdings in Ralliant Corporation $RAL

Hsbc Holdings PLC reduced its holdings in shares of Ralliant Corporation (NYSE:RAL) by 82.2% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 9,188 shares of the company’s stock after selling 42,312 shares during the quarter. Hsbc Holdings PLC’s holdings in Ralliant were worth $379,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in RAL. Danske Bank A S acquired a new stake in shares of Ralliant during the 4th quarter worth about $25,000. Allworth Financial LP lifted its stake in Ralliant by 134.4% during the fourth quarter. Allworth Financial LP now owns 511 shares of the company’s stock worth $26,000 after purchasing an additional 293 shares during the last quarter. V Square Quantitative Management LLC acquired a new position in Ralliant in the fourth quarter valued at approximately $26,000. Palisade Asset Management LLC acquired a new position in Ralliant in the third quarter valued at approximately $26,000. Finally, Rothschild Investment LLC increased its stake in Ralliant by 98.1% in the fourth quarter. Rothschild Investment LLC now owns 612 shares of the company’s stock valued at $31,000 after purchasing an additional 303 shares during the last quarter.

Ralliant Trading Down 1.8%

NYSE:RAL opened at $65.78 on Friday. The stock’s 50 day moving average price is $67.20 and its 200 day moving average price is $54.34. The company has a market capitalization of $7.36 billion and a PE ratio of -6.06. The company has a quick ratio of 1.05, a current ratio of 1.52 and a debt-to-equity ratio of 0.75. Ralliant Corporation has a 52-week low of $37.27 and a 52-week high of $75.41.

Ralliant (NYSE:RAL) last released its quarterly earnings results on Thursday, July 30th. The company reported $0.68 EPS for the quarter, topping the consensus estimate of $0.63 by $0.05. Ralliant had a positive return on equity of 14.97% and a negative net margin of 56.38%.The company had revenue of $567.80 million for the quarter. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. On average, research analysts anticipate that Ralliant Corporation will post 2.88 EPS for the current year.

Ralliant Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 23rd. Stockholders of record on Monday, June 8th were issued a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend was Monday, June 8th. Ralliant’s payout ratio is presently -1.83%.

Analysts Set New Price Targets

A number of research firms have weighed in on RAL. Oppenheimer raised their price objective on shares of Ralliant from $50.00 to $65.00 and gave the stock an “outperform” rating in a report on Wednesday, May 13th. Zacks Research upgraded shares of Ralliant from a “hold” rating to a “strong-buy” rating in a report on Tuesday, June 30th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Ralliant in a research report on Monday, May 4th. Morgan Stanley lifted their price target on shares of Ralliant from $68.00 to $85.00 and gave the stock an “overweight” rating in a research note on Tuesday, June 23rd. Finally, Wall Street Zen cut shares of Ralliant from a “buy” rating to a “hold” rating in a research report on Sunday, July 26th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Ralliant has an average rating of “Moderate Buy” and a consensus target price of $75.70.

More Ralliant News

Here are the key news stories impacting Ralliant this week:

• Positive Sentiment: Quarterly results exceeded expectations: Ralliant reported second-quarter revenue of approximately $568 million, up 13% year over year, and adjusted EPS of $0.68 versus the $0.63 consensus estimate. Adjusted net earnings were $76 million, while net earnings were $57 million. Ralliant Reports Second Quarter 2026 Results and Raises Full Year Guidance
• Positive Sentiment: Full-year and third-quarter outlooks topped consensus: Ralliant guided third-quarter EPS to $0.72-$0.78 and revenue to $570 million-$590 million, above analyst estimates of $0.68 and $556.4 million, respectively. Full-year 2026 adjusted EPS guidance was raised to $2.76-$2.90 from an analyst consensus of $2.65, with revenue expected around $2.25 billion-$2.30 billion. Ralliant forecasts 2026 revenue and productivity savings
• Positive Sentiment: Cost-reduction efforts could support future margins: Ralliant’s enterprise productivity program is targeting $50 million-$60 million in annualized run-rate savings by 2028, providing a potential boost to earnings and cash flow.
• Positive Sentiment: Analysts raised targets: Citigroup increased its target to $82 and initiated a “buy” rating, Truist raised its target to $82 while reaffirming “buy,” and RBC lifted its target to $73 while maintaining a “sector perform” rating. These targets imply meaningful upside from the recent trading level. Benzinga analyst actions
• Neutral Sentiment: Trading volatility increased: RAL experienced a temporary limit-up/limit-down trading pause during the earnings session, signaling elevated short-term volatility rather than a fundamental change in the business.
• Negative Sentiment: Valuation and execution risks remain: Despite the adjusted earnings beat, investors may continue to focus on Ralliant’s reported profitability, integration or productivity-program execution, and the gap between the stock’s recent price and analyst targets.

Ralliant Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.